Common use of Electronic Copy Clause in Contracts

Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. THE BOARD OF TRUSTEES OF THE XXXXXX XXXXXXXX JUNIOR UNIVERSITY Signature: /s/ Xxxxxxx Xxxxx Name: Xxxxxxx Xxxxx Title: Acting Director, Office of Technology Licensing Date: March 24, 2015 Alexo Therapeutics International Signature: /s/ Xxxxx Xxxxxxx Name: Xxxxx Xxxxxxx Title: Chair, Board of Directors Date: March 24, 2015 *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. [***] *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Stanford Docket No. S This report is provided pursuant to the license agreement between Stanford University and (Alexo Name) License Agreement Effective Date: Name(s) of Licensed Products being reported: Report Covering Period Yearly Maintenance Fee $ Number of Sublicenses Executed Gross Revenue U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Net Sales U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Royalty Calculation Royalty Subtotal $ Credit $ Royalty Due $ Comments: *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. The Board of Trustees of the Xxxxxx Xxxxxxxx Junior University (“STANFORD”); and Alexo Therapeutics International a Cayman Islands exempted company, with a mailing address at [951 Xxxxxxx Xxxx, Xxxxx 000, Xxxxx Xxx Xxxxxxxxx, XX 00000], (“ALEXO”); have agreed to use the law firm of (“FIRM”) to prepare, file and prosecute the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”).

Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. THE BOARD OF TRUSTEES OF THE XXXXXX XXXXXXXX JUNIOR UNIVERSITY Signature: /s/ Xxxxxxx Xxxxx Xxxxxxxxx Xx Name: Xxxxxxx Xxxxx Xxxxxxxxx Xx Title: Acting Director, Office of Technology Licensing Executive Director Date: March 24November 19, 2015 Alexo Therapeutics International Signature: FORTY SEVEN, INC. Signature /s/ Xxxxx Xxxxxxx Xxxxxxxx XxxXxxxxx Name: Xxxxx Xxxxxxx Xxxxxxxx XxxXxxxxx Title: Chair, Board of Directors CEO Date: March 24November 19, 2015 [*** ] = Certain confidential information contained in this agreement document, marked by brackets, has been omitted and filed separately with the Securities and Exchange CommissionCommission pursuant to Rule 406 of the Securities Act of 1933, as amended. Appendix A - Milestones [**] [*] indicates that text has been omitted and is the subject of a = Certain confidential treatment request. [***] *** Certain information contained in this agreement document, marked by brackets, has been omitted and filed separately with the Securities and Exchange CommissionCommission pursuant to Rule 406 of the Securities Act of 1933, as amended. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Appendix B – Sample Reporting Form Stanford Docket No. S S- This report is provided pursuant to the license agreement between Stanford University and (Alexo Company Name) License Agreement Effective Date: Name(s) of Licensed Products being reported: Report Covering Period Yearly Maintenance Fee $ Number of Sublicenses Executed Gross Revenue U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Net Sales U.S. Gross Revenue Net Sales Non-U.S. Gross Revenue Net Sales $ $ Royalty Calculation Royalty Subtotal $ Credit $ Royalty Due $ Comments: [*** ] = Certain confidential information contained in this agreement document, marked by brackets, has been omitted and filed separately with the Securities and Exchange CommissionCommission pursuant to Rule 406 of the Securities Act of 1933, as amended. [***] indicates that text has been omitted Appendix C – Client and is the subject of a confidential treatment request. Billing Agreement The Board of Trustees of the Xxxxxx Xxxxxxxx Junior University (“STANFORD”); and Alexo Therapeutics International a Cayman Islands exempted companyCorporation of the State of , with a mailing address principal place of business at [951 Xxxxxxx Xxxx, Xxxxx 000, Xxxxx Xxx Xxxxxxxxx, XX 00000], (“ALEXOCOMPANY”); have agreed to use the law firm of (“FIRM”) to prepare, file and prosecute the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”).

Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. THE BOARD OF TRUSTEES OF THE XXXXXX XXXXXXXX JUNIOR UNIVERSITY Signature: Signature /s/ Xxxxxxx Xxxxx Name: Xxxxxxx Xxxxx Title: Xxxx Xxxxxxxxx Name Xxxx Xxxxxxxxx Title Acting Director, Office of Technology Licensing Date: March 24Director Date October 27, 2015 Alexo Therapeutics International Signature: EICCOSE, LLC. Signature /s/ Xxxxx Xxxxxxx Name: Xxxx Name Xxxxx Xxxxxxx Title: Chair, Board of Directors Date: March 24, 2015 **Xxxx Title President and CEO Date [ * ] = Certain confidential information contained in this agreement has been omitted and document, marked by brackets, is filed separately with the Securities and Exchange CommissionCommission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. [***EICCOSE DEVELOPMENT AND REGULATORY PLAN FOR LTB4 INHIBITORS IN LYMPHEDEMA [ * ] indicates that text has been omitted and is the subject of a [ * ] = Certain confidential treatment request. [***] *** Certain information contained in this agreement has been omitted and document, marked by brackets, is filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Stanford Docket No. S This report is provided Commission pursuant to Rule 24b-2 of the license agreement between Stanford University and Securities Exchange Act of 1934, as amended. STANFORD DOCKET NO. S14-323 THIS REPORT IS PROVIDED PURSUANT TO THE LICENSE AGREEMENT BETWEEN STANFORD UNIVERSITY AND (Alexo NameEICCOSE, LLC) License Agreement Effective DateLICENSE AGREEMENT EFFECTIVE DATE: Name(s) of Licensed Products being reported: Report Covering Period Yearly Maintenance Fee REPORT COVERING PERIOD YEARLY MAINTENANCE FEE $ Number of Sublicenses Executed Gross Revenue U.S. Gross Revenue Non-U.S. Gross Revenue NUMBER OF SUBLICENSES EXECUTED NET SALES $ ROYALTY CALCULATION ROYALTY SUBTOTAL $ Net Sales U.S. Gross Revenue Non-U.S. Gross Revenue CREDIT $ ROYALTY DUE $ Royalty Calculation Royalty Subtotal $ Credit $ Royalty Due $ CommentsCOMMENTS: **[ * ] = Certain confidential information contained in this agreement has been omitted and document, marked by brackets, is filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. The Board of Trustees Commission pursuant to Rule 24b-2 of the Xxxxxx Xxxxxxxx Junior University (“STANFORD”); and Alexo Therapeutics International a Cayman Islands exempted companySecurities Exchange Act of 1934, with a mailing address at [951 Xxxxxxx Xxxx, Xxxxx 000, Xxxxx Xxx Xxxxxxxxx, XX 00000], (“ALEXO”); have agreed to use the law firm of (“FIRM”) to prepare, file and prosecute the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”)as amended.

Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. THE BOARD OF TRUSTEES OF THE XXXXXX LELXXX XXXXXXXX JUNIOR XXNIOR UNIVERSITY Signature: /s/ Xxxxxxx Xxxxx Name: Xxxxxxx Xxxxx Title: Acting Director, Office of Technology Licensing Date: March 24OCEAN PROMISE, 2015 Alexo Therapeutics International INC. Signature: /s/ Xxxxx Xxxxxxx Name: Xxxxx Xxxxxxx Title: Chair, Board of Directors Date: March 24AMENDED AND RESTATED NONEXCLUSIVE LICENSE AGREEMENT S20-122: MW 6/25/2020 Appendix A – Progress Report Sent by email to Stanford OTL at finxxxx@xxxxxxx.xxxxxxxx.xxx xxd infx@xxxxxxx.xxxxxxxx.xxx xxr the calendar year XXXX, 2015 *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. [***] *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Stanford Docket No. S This report is provided pursuant to paragraph 6.2 of the license agreement Amended and Restated Non-Exclusive License Agreement for Covid-19 Related Technology (“License Agreement”) between Stanford University and Ocean, effective March 3, 2021 A. List all Stanford dockets currently covered by the License Agreement. State whether any dockets have been added or dropped from the agreement in the past year. B. Summarize progress made with Licensed Product during the past year (Alexo Name) 2-4 paragraphs), including: work completed, key scientific discoveries, ongoing work-in-progress, plans for introducing Licensed Product to market, other relevant information. C. Status of Diligence Milestones that came due in the past year (per Section 6.1 / Appendix A of License Agreement Effective DateAgreement). Use format below; bold text indicates required info. Add rows to table as needed. Milestone Status By , 20XX Milestone # [ ] from License Agreement: Name(s) Completed / Not Completed [brief description of Licensed Products being reported: Report Covering Period Yearly Maintenance Fee $ Number of Sublicenses Executed Gross Revenue U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Net Sales U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Royalty Calculation Royalty Subtotal $ Credit $ Royalty Due $ Comments: *** Certain information in this agreement has been omitted status and filed separately with the Securities and Exchange Commissionrelevant dates] Completed. [***OR] indicates that text has been omitted Not completed. By , 20XX Milestone # [ ] from License Agreement: Completed / Not Completed [brief description of status and is relevant dates] Completed. [OR] Not Completed. D. Describe any significant corporate transactions during the subject of a confidential treatment request. The Board of Trustees of the Xxxxxx Xxxxxxxx Junior University (“STANFORD”); past year. E. Describe future plans, including estimated total development time remaining before Licensed Product will be commercialized. F. Update company contacts for progress reports, patent prosecution and Alexo Therapeutics International a Cayman Islands exempted companyfinancial information, with a mailing address at [951 Xxxxxxx Xxxx, Xxxxx 000, Xxxxx Xxx Xxxxxxxxx, XX 00000], (“ALEXO”); have agreed to use the law firm of (“FIRM”) to prepare, file and prosecute the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”)if needed.